Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Prostate. 2012 Apr;72(5):514-22. doi: 10.1002/pros.21453. Epub 2011 Jul 14.

Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model.

Author information

  • 1Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Abstract

BACKGROUND:

The CD8 T-cell response to prostate and other cancers is often functionally diminished or absent. This may occur via deletion of tumor-specific T cells, through acquisition of an anergic phenotype, or via active suppression mediated by another population of cells.

METHODS:

We used a double transgenic model in which mice express CD8 T cells specific for a prostate/prostate cancer antigen to study the response of CD8 T cells to evolving autochronous prostate tumors in TRAMP mice. CD8 T cells were analyzed for functionality by measuring IFN-γ production via flow cytometry and via an in vivo CTL killing assay. In addition, pathological scoring of the prostates of the double transgenic mice was compared to scoring of tumor burden prostates of ProTRAMP mice.

RESULTS:

Tumor-specific CD8 T cells were not grossly deleted in these animals, but evidenced a clearly non-functional phenotype. Interestingly, full lytic function was rapidly recovered upon removal from tumor-bearing mice.

CONCLUSIONS:

These data indicate a role for continuous antigen exposure in the maintenance of tumor-specific CD8 T-cell tolerance to prostate cancer.

Copyright © 2011 Wiley Periodicals, Inc.

PMID:
21761425
[PubMed - indexed for MEDLINE]
PMCID:
PMC3248615
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk